Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 80
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00193115 | Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer | ||
| NCT00390429 | Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | ||
| NCT00118508 | The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study) | ||
| NCT00211224 | Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) | ||
| NCT00118131 | Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | ||
| NCT00095654 | The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial | ||
| NCT00527761 | Taxotere/Temodar/Cisplatin Study in Melanoma Patients | ||
| NCT00193089 | Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer | ||
| NCT00151073 | Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate | ||
| NCT00238615 | Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC | ||
| NCT00113347 | Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) | ||
| NCT01652820 | Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer | ||
| NCT00176059 | Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients | ||
| NCT00193050 | Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer | ||
| NCT00257348 | Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer | ||
| NCT00183794 | Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma | ||
| NCT00122564 | Study of HIV-1 Rgp-160 Administered by Mucosal Routes in Healthy Volunteers | ||
| NCT00068341 | Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer | ||
| NCT00193284 | Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer | ||
| NCT00002662 | Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer | ||
| NCT00189449 | Effects of Long-Term Treatment With Nasally Inhaled Triamcinolone Acetonide in Children With Allergic Rhinitis | ||
| NCT00177255 | A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers | ||
| NCT00193245 | Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer | ||
| NCT01640782 | Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach | ||
| NCT00288444 | Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer | ||
| NCT00268593 | Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer | ||
| NCT00118053 | Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer | ||
| NCT00168896 | A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage | ||
| NCT00087035 | Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer | ||
| NCT00193011 | Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer | ||
| NCT00214058 | Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer | ||
| NCT00048087 | Iressa/Docetaxel in Non-Small-Cell Lung Cancer | ||
| NCT00193180 | Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer | ||
| NCT00066885 | Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer | ||
| NCT00220064 | A Phase II Trial Evaluating Irinotecan Plus 5FU/LV in Patients With Relapsed/Refractory Upper GI Tumours | ||
| NCT00256789 | Once Weekly Radiation for Lung Cancer With Chemotherapy | ||
| NCT00216008 | Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation. | ||
| NCT00193323 | Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients | ||
| NCT00005800 | Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer | ||
| NCT00193232 | Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer | ||
| NCT00193271 | Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer | ||
| NCT00193024 | Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer | ||
| NCT00194558 | Outcomes and Cost Consequences of Using an Internet Co-Management Module to Improve the Quality of Type 1 Diabetes Care | ||
| NCT00043576 | ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere | ||
| NCT00240747 | Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients | ||
| NCT00189670 | Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer | ||
| NCT00196651 | HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection | ||
| NCT00221845 | Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients | ||
| NCT00198237 | Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer | ||
| NCT00270894 | Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients |
